REMINDER: Our user survey closes on Friday, please submit your responses here.
I think its most likely (for your 3 points) down to favorable terms you are able to get when negotiating with smaller partners as opposed more aggressive terms you may get with bigger ones...any bigger partner, big pharma, government would want to lock up significant upside and remove it from you... that being said im no expert and actually have no idea whether these partners are actually "small" as you describe them...
The 7 directors of the company will take these decisions and vote, not rm alone
https://www.synairgen.com/about-us/synairgens-directors/
seeing some approvals appearing in the media from EMA prime which wasnt announced on the website we ve been tracking...
which confirms that they wont announce it there for confidential reasons and we may see a RNS/annoucement soon...
http://www.pharmaceuticaldaily.com/valnevas-chikungunya-vaccine-candidate-awarded-ema-prime-designation/
In fact read this article which explains why vaccines wont solve anything in the short-mid term
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30151-8/fulltext
pmjh i think you refer to those dates: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/prime-eligibility-requests-2020-deadlines-submission-timetable-assessment_en.pdf
Lets hope they submitted before august 26th, otherwise we re looking at the November meeting for final approval
a very interesting take on what to expect from vaccines... at least for the next few years
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30151-8/fulltext
i have probably refreshed this page 500 times already today
https://www.ema.europa.eu/en/news-events/whats-new